1-5 of 5
Martijn Brugman, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improving Hematopoietic Stem Cell Based Gene Therapy By Targeting CD133+ Cells

Benjamin Goebel, MD, Christian Brendel, PhD, Daniela Abriss, Sabrina Kneissl, PhD, Martijn Brugman, PhD, Christian J. Buchholz, PhD, Hubert Serve, MD, Manuel Grez, PhD
Journal: Blood
Blood (2013) 122 (21): 4202.
https://doi.org/10.1182/blood.V122.21.4202.4202
Published: 2013
Journal Articles

Receptor Tyrosine Kinases, Notch Mutations and PTEN Loss Converge On mTOR in T-ALL and Cause Addiction to Cap Dependent mRNA Translation.

Adrian Schwarzer, MD, Helmut Holtmann, PhD, Martijn Brugman, PhD, Johann Meyer, PhD, Doris Steinemann, PhD, Brigitte Schlegelberger, Zhixiong Li, MD, Christopher Baum, MD
Journal: Blood
Blood (2012) 120 (21): 2415.
https://doi.org/10.1182/blood.V120.21.2415.2415
Published: 2012
Journal Articles

Evi-1 Regulates Myelopoiesis and Hematopoietic Stem Cell Development in Zebrafish and Human Pluripotent Stem Cells

Martina Konantz, PhD, Matthias Grauer, Sarah Grzywna, Martijn Brugman, PhD, Lothar Kanz, MD, In-Hyun Park, PhD, George Q. Daley, MD, PhD, Christopher Baum, MD, Claudia Lengerke, MD
Journal: Blood
Blood (2011) 118 (21): 1281.
https://doi.org/10.1182/blood.V118.21.1281.1281
Published: 2011
Journal Articles

Evidence for Cooperation of Receptor Tyrosine Kinases and Activating NOTCH Mutations to Hyperactivate mTOR in T-Cell Leukemia: A Rationale Basis for Targeted Therapy

Adrian Schwarzer, MD, Johann Meyer, PhD, Martijn Brugman, PhD, Axel Schambach, MD PhD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Doris Steinemann, PhD, Brigitte Schlegelberger, M.D., Christopher Baum, MD, Zhixiong Li, MD
Journal: Blood
Blood (2011) 118 (21): 1381.
https://doi.org/10.1182/blood.V118.21.1381.1381
Published: 2011
Journal Articles

Somatic Gene Therapy for X-Linked Severe Combined Immunodeficiency Using a Self-Inactivating Modified Gammaretroviral Vector Results in An Improved Preclinical Safety Profile and Early Clinical Efficacy in a Human Patient

Sung-Yun Pai, MD, Luigi Daniele Notarangelo, MD, Chad Harris, Federica Cattaneo, MD, Matthew Wladkowski, Myriam Armant, PhD, Grace S. Kao, MD, Matthew Wielgosz, Arthur W. Nienhuis, MD, Ute Modlich, DVM, PhD, Martijn Brugman, PhD, Axel Schambach, MD PhD, Michael Rothe, Susannah I Thornhill, PhD, H. Bobby Gaspar, Kathryn Parsley, PhD, Samantha Cooray, PhD, Elke Grassman, Ph.D., Frederic Bushman, PhD, Sally Shupien, Matias Oleastro, MD, Salima Hacein-Bey-Abina, Alain Fischer, MD, Marina Cavazzana-Calvo, MD, PhD, Punam Malik, MD, Alexandra Filipovich, MD, Donald B. Kohn, MD, Christopher Baum, MD, David A. Williams, MD, Adrian J Thrasher, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 164.
https://doi.org/10.1182/blood.V118.21.164.164
Published: 2011